Anti-RBD Ig, anti-RBD IgG, anti-S IgA and neutralizing activities in vaccinated individuals

This is a cross-sectional study in which leftover sera samples from participants vaccinating with either heterologous inactivated CoronaVac followed by BNT162b2 vaccine (n=76), two-dose CoronaVac (n=170), or two-dose BNT162b2 regimen (n=19). The homologous group received vaccine at 21-28 days apart. The heterologous CoronaVac/BNT162b2 received vaccine at varying intervals according to the availability of the second dose vaccine. Blood samples were collected between 21and 35 days after the second dose vaccination. Serological testing against SARS-CoV-2 was performed on serum samples.